Clinical Research Directory
Browse clinical research sites, groups, and studies.
6 clinical studies listed.
Filters:
Tundra lists 6 Hypopharynx Cancer clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07063212
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
Gender: All
Ages: 18 Years - Any
Updated: 2026-02-19
2 states
NCT05798780
The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors
The purpose of the study is to design a physical activity and dietary intervention for head and neck cancer patients.
Gender: All
Ages: 18 Years - Any
Updated: 2025-12-04
1 state
NCT06706401
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.
Gender: All
Ages: 18 Years - Any
Updated: 2025-11-18
NCT05337631
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.
Gender: All
Ages: 65 Years - Any
Updated: 2025-03-25
3 states
NCT06611137
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Gender: All
Ages: 18 Years - 70 Years
Updated: 2024-09-26
1 state
NCT06554028
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
This study is a prospective, single-arm, single-center, phase II study. The goal of this clinical trial is to explore the therapeutic value of the treatment model of "tislelizumab combined with chemotherapy followed by radiotherapy/adaptive surgery" on larynx Preservation of locally advanced hypopharyngeal cancer and laryngeal cancer.
Gender: All
Ages: 18 Years - 70 Years
Updated: 2024-08-14
1 state